Novo Nordisk Completes Acquisition of 3 Manufacturing Sites
Ticker: NONOF · Form: 6-K · Filed: Dec 18, 2024 · CIK: 353278
Sentiment: neutral
Topics: acquisition, manufacturing, capacity-expansion
Related Tickers: NVO
TL;DR
Novo Nordisk just bought 3 factories from Novo Holdings to boost production.
AI Summary
Novo Nordisk announced on December 18, 2024, the completion of its acquisition of three manufacturing sites from Novo Holdings A/S. This acquisition is a consequence of Novo Holdings' earlier acquisition of Catalent, which was also finalized.
Why It Matters
This move expands Novo Nordisk's manufacturing capacity, potentially supporting increased production of its key pharmaceutical products.
Risk Assessment
Risk Level: low — The filing is a routine report on the completion of a previously announced transaction, with no new material risks introduced.
Key Numbers
- 3 — Manufacturing Sites (Number of sites acquired by Novo Nordisk from Novo Holdings.)
Key Players & Entities
- Novo Nordisk (company) — Acquiring company
- Novo Holdings A/S (company) — Seller of manufacturing sites
- Catalent (company) — Company whose acquisition by Novo Holdings triggered this transaction
- December 18, 2024 (date) — Date of announcement and completion
FAQ
What is the primary purpose of Novo Nordisk acquiring these three manufacturing sites?
The acquisition is intended to expand Novo Nordisk's manufacturing capacity, following Novo Holdings' acquisition of Catalent.
When was the acquisition of the manufacturing sites completed?
The acquisition was completed on December 18, 2024.
Who is the seller of the three manufacturing sites to Novo Nordisk?
The seller is Novo Holdings A/S.
What event preceded Novo Nordisk's acquisition of these manufacturing sites?
The acquisition of the manufacturing sites by Novo Nordisk followed the finalization of Novo Holdings' acquisition of Catalent.
Where is Novo Nordisk headquartered?
Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-12-18 13:49:34
Filing Documents
- f6k_121824.htm (6-K) — 15KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-24-006991.txt ( ) — 155KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: December 18, 2024 NOVO NORDISK A/S Lars Fruergaard Jørgensen Chief Executive Officer